Trials / Completed
CompletedNCT00305487
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Efficacy of Ciclesonide (200mcg and 100mcg, Once Daily) Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 6 to 11 Years of Age
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 660 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 6 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to determine the efficacy and safety of ciclesonide nasal spray in children with seasonal allergic rhinitis. Ciclesonide will be administered intranasally at two dose levels once daily. The study consists of a baseline period (1 to 3 weeks) and a treatment period (2 weeks).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ciclesonide nasal spray |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2006-10-01
- Completion
- 2006-10-01
- First posted
- 2006-03-22
- Last updated
- 2016-11-30
Locations
71 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00305487. Inclusion in this directory is not an endorsement.